Bristol Myers Squibb Plans Biopharmaceutical R&D Center

Published 3-10-2022
  • Bristol Myers Squibb - Alexandria Point
  • Bristol Myers Squibb - Alexandria Point

    Courtesy of Alexandria Real Estate Equities.

Bristol Myers Squibb is partnering with Alexandria Real Estate Equities to create a 427,000-rsf R&D center in San Diego. Located in the Alexandria Point development, the leased facility will provide core labs for the creation of advanced biopharmaceutical therapies. Housing nearly 600 researchers and staff members, the collaborative building will consolidate employees from several regional campuses into a flexible working ecosystem for discovery and innovation. Comprising two wings connected by a five-story atrium, the structure will feature myriad balconies, a rooftop deck, and a faceted façade that mitigates solar heat gain while admitting abundant natural light. Groundbreaking is slated for mid-2022 with occupancy expected in 2025. LEED Gold sustainable design certification will be sought for the project.

Upon completion, Alexandria Point will provide over two million sf of mission-critical laboratory and office space supported by a state-of-the-art central plant. The amenity-rich campus will include sophisticated conference venues, fitness and wellness facilities, and expansive green spaces.